Protonitazepyne

Protonitazepyne (N-pyrrolidino protonitazene) is a benzimidazole derivative with opioid effects, which has been sold as a designer drug over the internet, first being mentioned in mid 2022 and definitively identified in drug seizures in…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Protonitazepyne (N-pyrrolidino protonitazene) is a benzimidazole derivative with opioid effects, which has been sold as a designer drug over the internet, first being mentioned in mid 2022 and definitively identified in drug seizures in Canada in early 2023 and Ireland in late 2023. It has since been identified by CanTEST in May 2024 in Australia and in late 2025 in Brazil by the State University of Campinas poison control center.

It is an analogue of protonitazene where the N,N-diethyl group has been substituted for pyrrolidine group. While formal studies into its pharmacology have yet to be carried out, it has an in vitro potency approximately 350x times that of morphine.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1376942549 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.